

eReferences

- e1. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. *Cephalalgia* 2018;38:1–211.
- e2. Antunes C, Aleem A, Curtis SA. Gastroesophageal reflux disease. Statpearls [internet]. Treasure Island (FL): StatPearls Publishing, 2020.
- e3. Thorek P. Blood supply of the gut. *Anatomy in surgery*. New York, NY, USA: Springer, 1985.
- e4. Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American neurogastroenterology and motility society and the cyclic vomiting syndrome association. *Neurogastroenterol Motil* 2019;31 Suppl 2:e13604.
- e5. Naphthali K, Koloski N, Talley NJ. Abdominal migraine. *Cephalalgia* 2016;36:980–986.
- e6. American Migraine Foundation. What you need to know about abdominal migraine. Available at: <https://americanmigrainefoundation.org/resource-library/what-is-abdominal-migraine/> (accessed September 17, 2020) [online].
- e7. Sleisenger MH, Fordtran JS, Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's gastrointestinal and liver disease. Vol. 1 : Pathophysiology, diagnosis, management, 9th ed. ed. Philadelphia: Saunders/Elsevier, 2010.
- e8. Aurora SK, Kori SH, Barrodale P, McDonald SA, Haseley D. Gastric stasis in migraine: More than just a paroxysmal abnormality during a migraine attack. *Headache* 2006;46:57–63.
- e9. Internal clinical guidelines team (uk). Coeliac disease: Recognition, assessment and management. London, 2015.
- e10. Griauzdaitė K, Maselis K, Žvirblienė A, Vaitkus A, Jančiauskas D, Banaitytė-Baleišienė I, Kupčinskas L, Rastenyte D. Associations between migraine, celiac disease, non-celiac gluten sensitivity and activity of diamine oxidase. *Med Hypotheses*. 2020 Sep;142:109738. doi: 10.1016/j.mehy.2020.109738. Epub 2020 Apr 11. PMID: 32416409
- e11. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. *Gastroenterology* 2016;150:1393–1407.
- e12. Gazerani P, Cairns BE. Dysautonomia in the pathogenesis of migraine. *Expert Rev Neurother* 2018;18:153–165.
- e13. Yablon LA, Mauskop A. Magnesium in headache. In: Vink R, Nechifor M, editors. *Magnesium in the Central Nervous System* [Internet]. Adelaide (AU): University of Adelaide Press; 2011. PMID: 29920023.
- e14. Arzani M, Jahromi SR, Ghorbani Z, et al. Gut-brain axis and migraine headache: A comprehensive review. *J Headache Pain* 2020;21:15.
- e15. Snell RS. *Clinical neuroanatomy*, 7th ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 2010.
- e16. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. *Physiol Rev* 2004;84:903–934.

- e17. Aamodt AH, Stovner LJ, Hagen K, Zwart JA. Comorbidity of headache and gastrointestinal complaints. The head-hunt study. *Cephalalgia* 2008;28:144–151.
- e18. Aydinlar EI, Dikmen PY, Tiftikci A, et al. Igg-based elimination diet in migraine plus irritable bowel syndrome. *Headache* 2013;53:514–525.
- e19. Bektas H, Karabulut H, Doganay B, Acar B. Allergens might trigger migraine attacks. *Acta Neurol Belg* 2017;117:91–95.
- e20. Pawlik WW, Obuchowicz R, Biernat J, Sendur R, Jaworek J. Role of calcitonin gene related peptide in the modulation of intestinal circulatory, metabolic, and myoelectric activity during ischemia/reperfusion. *J Physiol Pharmacol* 2000;51:933–942.
- e21. Lai NY, Musser MA, Pinho-Ribeiro FA, et al. Gut-innervating nociceptor neurons regulate peyer's patch microfold cells and SFB levels to mediate salmonella host defense. *Cell* 2020;180:33–49 e22.
- e22. Gerner RR, Raffatellu M. Gut pain sensors help to combat infection. *Nature* 2020;580:594–595.
- e23. Assas BM, Pennock JI, Miyan JA. Calcitonin gene-related peptide is a key neurotransmitter in the neuro-immune axis. *Front Neurosci* 2014;8:23.
- e24. Blumenfeld A, Durham PL, Feoktistov A, Hay DL, Russo AF, Turner I. Hypervigilance, allostatic load, and migraine prevention: Antibodies to CGRP or receptor. *Neurol Ther* 2021;doi:10.1007/s40120-021-00250-7.
- e25. Di Giovangiulio M, Verheijden S, Bosmans G, Stakenborg N, Boeckxstaens GE, Matteoli G. The neuromodulation of the intestinal immune system and its relevance in inflammatory bowel disease. *Front Immunol* 2015;6:590.
- e26. Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/cgrp family of peptides: Iuphar review 25. *Br J Pharmacol* 2018;175:3–17.
- e27. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: Potential role of vagal inhibition. *Am J Physiol Gastrointest Liver Physiol* 2000;278:G946–951.
- e28. Falkenberg K, Bjerg HR, Olesen J. Two-hour CGRP infusion causes gastrointestinal hyperactivity: Possible relevance for CGRP antibody treatment. *Headache* 2020.
- e29. Russo AF. Calcitonin gene-related peptide (CGRP): A new target for migraine. *Annu Rev Pharmacol Toxicol* 2015;55:533–552.
- e30. Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: Physiology and pathophysiology. *Physiol Rev* 2014;94:1099–1142.
- e31. Bohn KJ, Li B, Huang X, et al. CGRP receptor activity in mice with global expression of human receptor activity modifying protein 1. *Br J Pharmacol* 2017;174:1826–1840.
- e32. Moore E, Fraley ME, Bell IM, et al. Characterization of ubrogepant: A potent and selective antagonist of the human calcitonin gene-related peptide receptor. *J Pharmacol Exp Ther* 2020;373:160-166.
- e33. Biohaven Pharmaceuticals Inc. Biohaven's oral zavegepant, a third generation CGRP receptor antagonist, receives authorization to proceed from FDA and achieves first in human dosing [online]. Available at: <https://www.biohavenpharma.com/investors/news-events/press-releases/09-10-2020> Accessed 14 October 2021.

- e34. FAERS database. Food and drug administration adverse events reporting system public dashboard. Available at: <https://www.Fda.Gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard>. (accessed February 25, 2021) [online].
- e35. Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and drug administration adverse event reporting system (FAERS). *Expert Opin Drug Saf* 2017;16:761-767
- e36. Dodick DW, Ashina M, Brandes JL, et al. Arise: A phase 3 randomized trial of erenumab for episodic migraine. *Cephalalgia* 2018;38:1026–1037.
- e37. Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. *N Engl J Med* 2017;377:2123–2132.
- e38. Amgen inc. Aimovig highlights of prescribing information. Available at: https://www.Accessdata.Fda.Gov/drugsatfda_docs/label/2018/761077s000lbl.Pdf. (Accessed September 17, 2020).
- e39. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial. *JAMA* 2018;319:1999–2008
- e40. Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: Promise-2. *Neurology* 2020;94:e1365–e1377.
- e41. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. *N Engl J Med* 2017;377:2113–2122.
- e42. Alex A, Vaughn C, Rayhill M. Safety and tolerability of 3 CGRP monoclonal antibodies in practice: A retrospective cohort study. *Headache* 2020;60:2454–2462.
- e43. Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ. Real-world patient experience with erenumab for the preventive treatment of migraine. *Headache* 2020;60:2014–2025.
- e44. Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. *J Headache Pain* 2020;21:61.
- e45. Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. *J Headache Pain* 2020;21:32.
- e46. Novartis Pharmaceuticals Corporation. Aimovig 140 mg solution for injection in pre-filled pen. Summary of product characteristics. Available at: <https://www.Medicines.Org.Uk/emc/product/10297/smpc> (accessed April 2020).
- e47. Eli Lilly and Company Limited. Emgality 120 mg solution for injection in pre-filled pen. Summary of product characteristics. Available at: <https://www.Medicines.Org.Uk/emc/product/10478> (accessed April 2020).
- e48. Eli Lilly and company. Emgality highlights of prescribing information. Available at: <https://pi.Lilly.Com/us/emgality-uspi.Pdf> (accessed April 06, 2021).
- e49. Teva Pharmaceuticals USA Inc. Ajovy (fremanezumab-vfrm) prescribing information. Available at: <https://www.Ajovy.Com/globalassets/ajovy/ajovy-pi.Pdf> (accessed October 14, 2020) [online].
- e50. Lundbeck Seattle Biopharmaceuticals, inc. Vyepti highlights of prescribing information. Available at:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf (accessed April 06, 2021)

- e51. Teva GmbH. Ajovy (fremanezumab-vfrm) summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/ajovy-epar-product-information_en.pdf (accessed October 14, 2020) [online].
- e52. Biohaven Pharmaceuticals Inc. Nurtec odt (rimegepant) us prescribing information. Available at: <https://www.nurtec.com/pi> (accessed October 14, 2020) [online].
- e53. Allergan Pharmaceuticals International Ltd. Ubrelvy (ubrogepant) us prescribing information. Available at: https://media.allergan.com/products/ubrelvy_pi.pdf (accessed October 14, 2020) [online].
- e54. Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The achieve ii randomized clinical trial. *JAMA* 2019;322:1887–1898.
- e55. Muller-Lissner S, Bassotti G, Coffin B, et al. Opioid-induced constipation and bowel dysfunction: A clinical guideline. *Pain medicine* (Malden, Mass) 2017;18:1837–1863.
- e56. Thapa N, Kappus M, Hurt R, Diamond S. Implications of the opioid epidemic for the clinical gastroenterology practice. *Curr Gastroenterol Rep* 2019;21:44
- e57. Cryer B, Kimmey MB. Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. *The American journal of medicine* 1998;105:20s–30s.
- e58. Shin SJ, Noh CK, Lim SG, Lee KM, Lee KJ. Non-steroidal anti-inflammatory drug-induced enteropathy. *Intest Res* 2017;15:446–455.
- e59. Sostres C, Gargallo CJ, Lanás A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. *Arthritis Res Ther* 2013;15 Suppl 3:S3.
- e60. Chia V, Park A, Goli V, Win N, Navetta NS, Xue F. Incidence of constipation in patients treated with commonly used migraine medications. *International Headache Congress*. Dublin, Ireland, 2019.
- e61. Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Vilchez JS, Rodriguez-Lopez CM. Pregabalin in the treatment of chronic migraine: An open-label study. *Clin Neuropharmacol* 2010;33:35–39.
- e62. Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. *Clin Neurol Neurosurg* 2008;110:979–984.
- e63. Loder E, Rizzoli P. Pharmacologic prevention of migraine: A narrative review of the state of the art in 2018. *Headache* 2018;58 Suppl 3:218–229.
- e64. Accord-UK Ltd. Amitriptyline 10 mg tablets bp. Summary of product characteristics. Available at: <https://www.medicines.org.uk/emc/product/5698/smpc> (accessed April 2020).
- e65. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: A meta-analysis. *World J Gastroenterol* 2009;15:1548–1553.
- e66. Garza I, Swanson JW. Prophylaxis of migraine. *Neuropsychiatr Dis Treat* 2006;2:281–291.

- e67. Aurobindo Pharma - Milpharm Ltd. Lisinopril tablets 10 mg. Summary of product characteristics. Available at: <https://www.Medicines.Org.Uk/emc/product/7143/smpc> (accessed April 2020).
- e68. Hunt R, Quigley E, Abbas Z, et al. Coping with common gastrointestinal symptoms in the community: A global perspective on heartburn, constipation, bloating, and abdominal pain/discomfort May 2013. *J Clin Gastroenterol* 2014;48:567–578.
- e69. Davies NM, Reynolds JK, Undeberg MR, Gates BJ, Ohgami Y, Vega-Villa KR. Minimizing risks of NSAIDS: Cardiovascular, gastrointestinal and renal. *Expert Rev Neurother* 2006;6:1643-1655.
- e70. Ali Khan M, Howden CW. The role of proton pump inhibitors in the management of upper gastrointestinal disorders. *Gastroenterol Hepatol (NY)* 2018;14:169-175.
- e71. US Food and Drug Administration. Drugs@fda: FDA-approved drugs [online]. Available at: <https://www.accessdata.fda.gov/scripts/cder/daf/>. Accessed 07 July 2021.
- e72. Datapharm. Electronic medicines compendium [online]. Available at: <https://www.medicines.org.uk/emc>. Accessed 07 July 2021.